FDA Approves New Drug for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

MONDAY, Jan. 23, 2023 (HealthDay News) -- The U.S. Food and Drug Administration has approved zanubrutinib (Brukinsa), a next-generation BTK inhibitor, for the treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
The approval was based on data from the phase 3 ALPINE trial, a head-to-head comparison of BTK inhibitors. Patients were randomly assigned to zanubrutinib or ibrutinib. Ibrutinib is a first-generation BTK inhibitor and the current standard treatment.
Jennifer R. Brown, M.D., Ph.D., from Dana-Farber Cancer Institute in Boston, led the ALPINE trial that found zanubrutinib-treated patients had a longer progression-free survival (PFS) at 29.6 months of follow-up (79.5 versus 67.3 percent). Furthermore, patients taking zanubrutinib had a lower rate of treatment discontinuation (26.3 versus 41.2 percent), including for heart disorders and cardiac events. The rate of atrial fibrillation or atrial flutter was lower with zanubrutinib (5.2 percent) versus ibrutinib (13.3 percent).
The FDA reported that the most common adverse reactions seen with zanubrutinib were a decrease in neutrophil count, upper respiratory tract infection, decrease in platelet count, hemorrhage, and musculoskeletal pain.
"I am encouraged that zanubrutinib has been approved for adults with chronic lymphocytic leukemia and small lymphocytic lymphoma and optimistic that many patients across the country will benefit from this approval," Brown said in a statement. "Our findings also found that zanubrutinib led to fewer side effects and adverse events than ibrutinib, leading to a better quality of life for patients."
Approval of Brukinsa (zanubrutinib) was granted to BeiGene.
Related Posts
Bipolar Disorder: What It Is, Symptoms & Treatments
TUESDAY, May 16, 2023 (HealthDay News) -- More than 10 million people in the...
One Gender May Excel at Reading What Others Are Feeling
FRIDAY, Dec. 30, 2022 (HealthDay News) -- A new study confirms what many...
ChatGPT Generates Differential Diagnoses With Similar Accuracy to Emergency Doctors
THURSDAY, Sept. 21, 2023 (HealthDay News) -- ChatGPT performance in generating...
COVID-19 Vaccination Greatly Reduced Morbidity, Mortality Burden in U.S.
WEDNESDAY, July 6, 2022 (HealthDay News) -- The COVID-19 vaccination program in...